- Home
- SNTI vs CLYM Comparison
SNTI vs CLYM Comparison
Compare SNTI & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CLYM
- Stock Information
- Founded
- SNTI 2016
- CLYM 2018
- Country
- SNTI United States
- CLYM United States
- Employees
- SNTI N/A
- CLYM N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- SNTI Health Care
- CLYM
- Exchange
- SNTI Nasdaq
- CLYM NYSE
- Market Cap
- SNTI 85.3M
- CLYM 83.1M
- IPO Year
- SNTI N/A
- CLYM 2021
- Fundamental
- Price
- SNTI $3.10
- CLYM $1.27
- Analyst Decision
- SNTI Strong Buy
- CLYM
- Analyst Count
- SNTI 1
- CLYM 0
- Target Price
- SNTI $12.00
- CLYM N/A
- AVG Volume (30 Days)
- SNTI 225.5K
- CLYM 123.6K
- Earning Date
- SNTI 05-06-2025
- CLYM 05-19-2025
- Dividend Yield
- SNTI N/A
- CLYM N/A
- EPS Growth
- SNTI N/A
- CLYM N/A
- EPS
- SNTI N/A
- CLYM N/A
- Revenue
- SNTI N/A
- CLYM N/A
- Revenue This Year
- SNTI N/A
- CLYM N/A
- Revenue Next Year
- SNTI N/A
- CLYM N/A
- P/E Ratio
- SNTI N/A
- CLYM N/A
- Revenue Growth
- SNTI N/A
- CLYM N/A
- 52 Week Low
- SNTI $1.52
- CLYM $1.05
- 52 Week High
- SNTI $16.94
- CLYM $10.23
- Technical
- Relative Strength Index (RSI)
- SNTI 41.06
- CLYM N/A
- Support Level
- SNTI $3.10
- CLYM N/A
- Resistance Level
- SNTI $3.61
- CLYM N/A
- Average True Range (ATR)
- SNTI 0.40
- CLYM 0.00
- MACD
- SNTI -0.07
- CLYM 0.00
- Stochastic Oscillator
- SNTI 9.50
- CLYM 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.